Is the Chinese name of Cemiplimab Cemiplimab?

Cemiplimab is a transliterated name of the drug, but it has not yet been officially launched in China, so its official Chinese name has not yet been officially confirmed. Cemiplimab, as an immune checkpoint inhibitor, is mainly used to treat certain types of cancer, including various skin cancers, non-small cell lung cancer, etc. Its mechanism is to block the interaction between programmed death receptor-1 (PD-1) and its ligand, thereby enhancing the body's immune response and enabling T cells to recognize and attack tumor cells more effectively.

Although cimepilimab has been approved and put into use in the international market, especially in the United States, Europe and other places, it is still in the clinical research and approval stage in China. Patients may not be able to use this drug directly when receiving treatment in China, which is undoubtedly a challenge for cancer patients who need new immunotherapy. At the same time, with the continuous development of cancer treatment methods in China, cimepilimab is expected to be approved in the domestic market in the future and become a treatment option for more patients.

The trade name of cimipilimab isLibtayo, which has achieved good clinical application results in some countries and has shown high patient tolerance. Clinical trials have shown that cimepilimab has significant efficacy in the treatment of certain cancers and can improve patients' survival rate and quality of life. However, the use of this drug may also be associated with some immune-related adverse reactions, including inflammation of the skin, endocrine and gastrointestinal tract. Therefore, during treatment, doctors will closely monitor the patient's health status and adjust the treatment plan in a timely manner to ensure the patient's safety and efficacy.

Reference materials:https://en.wikipedia.org/wiki/Cemiplimab